# A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

> **NCT04866108** · PHASE2 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 49 (estimated)

## Conditions studied

- Unresectable Metastatic Colorectal Cancer

## Interventions

- **DRUG:** fruquintinib plus capecitabine

## Key facts

- **NCT ID:** NCT04866108
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-08
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04866108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04866108, "A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04866108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*